Falcon Therapeutics

Falcon Therapeutics was a private biotechnology company developing personalized, tumor-homing cell therapies for brain cancer. Its approach used a patient’s own skin cells reprogrammed into autologous neural stem cells that were further engineered to seek out and destroy residual tumor cells, particularly in glioblastoma. The company emerged from research associated with the University of North Carolina at Chapel Hill and positioned its technology as a next-generation cell and gene therapy platform for solid tumors in the brain. Falcon Therapeutics appears to have remained at the preclinical stage and is now reported by multiple company databases as closed or out of business.